Respiratory syncytial virus bronchiolitis

Summary

Respiratory syncytial virus bronchiolitis (MONDO:0100286) is a disease and 8 clinical trials. Top therapeutic interventions include palivizumab. A subtype of respiratory syncytial virus infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	respiratory syncytial virus bronchiolitis
Mondo ID	MONDO:0100286
UMLS	C0276340
MedGen	547277
Is cancer (heuristic)	no

Also known as: RSV bronchiolitis

Disease family

This is a subtype of respiratory syncytial virus infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Mononegavirales infectious disease › respiratory syncytial virus infectious disease › respiratory syncytial virus bronchiolitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE4	1
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00361452	PHASE4	TERMINATED	Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study
NCT02442427	PHASE3	COMPLETED	Palivizumab Therapy for RSV-bronchiolitis
NCT01486758	PHASE2	COMPLETED	Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
NCT01140048	Not specified	COMPLETED	Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
NCT02618213	Not specified	COMPLETED	Comparison of High Flow Oxygenation Therapy and CPAP in Children With Bronchiolitis.
NCT03627572	Not specified	UNKNOWN	RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants
NCT04144816	Not specified	UNKNOWN	Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
NCT04925310	Not specified	UNKNOWN	Infection With Respiratory Syncytial Virus in Infants

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PALIVIZUMAB	4	1
CHEMBL4299381	0	1